Leumorphin (porcine) / Dynorphin B [1-29] / Prodynorphin (228-256), porcine peptide

Leumorphin (porcine) / Dynorphin B [1-29] / Prodynorphin (228-256), porcine peptide

• Handling and Storage of Synthetic Peptides
• Material Safety Data Sheets (MSDS)

Batch to batch variation of the purity

YGGFLRRQFKVVTRSQEDPNAYYEELFDV

H-Tyr-Gly-Gly-Phe-Leu-Arg-Arg-Gln-Phe-Lys-Val-Val-Thr-Arg-Ser-Gln-Glu-Asp-Pro-Asn-Ala-Tyr-Tyr-Glu-Glu-Leu-Phe-Asp-Val-OH

29

96.1%

C₁₆₁H₂₃₆N₄₂O₄₈

3527.91

16131065

Synthetic

Powder

Dynorphin B [1-29] was found in pig (Sus scrofa). Porcine dynorphin B-29, also referred to as leumorphin or prodynorphin (228-256), is a 29-amino acid endogenous opioid peptide derived from the precursor proenkephalin B. Its sequence is Tyr-Gly-Gly-Phe-Leu-Arg-Arg-Gln-Phe-Lys-Val-Val-Thr-Arg-Ser-Gln-Glu-Asp-Pro-Asn-Ala-Tyr-Tyr-Glu-Glu-Leu-Phe-Asp-Val. This peptide was chemically synthesized using solid-phase methods and purified through gel filtration, ion exchange, reverse phase liquid chromatography, and preparative high pressure liquid chromatography, achieving a purity of at least 99% as confirmed by HPLC, thin-layer chromatography, and paper electrophoresis. In binding experiments using mouse brain tissue, dynorphin B-29 displays equal affinity for μ and κ opioid receptors (KI values of 5.0 ± 0.7 nM and 5.3 ± 0.58 nM, respectively) and significant but lower affinity for δ receptors (KI of 18.4 ± 2.4 nM). In isolated tissue preparations, its potency to inhibit electrically evoked contractions varies across systems, being highest in the guinea pig ileum (IC50 of 7.54 ± 1.8 nM), followed by mouse vas deferens, rabbit vas deferens, and rat vas deferens, where only partial inhibition is observed. The presence of peptidase inhibitors further reduces IC50 values, particularly in rabbit vas deferens, indicating that the peptide is subject to enzymatic degradation in different tissues.

Normally, this peptide will be delivered in lyophilized form and should be stored in a freezer at or below -20 °C. For more details, please refer to the manual: Handling and Storage of Synthetic Peptides

• Sanchez-Blazquez P, Chang JK, Garzon J, Lee NM. Dynorphin B-29: chemical synthesis and pharmacological properties in opioid systems in vitro. Neuropeptides. 1984 Sep;4(5):369-74. doi: 10.1016/0143-4179(84)90112-4. PMID: 6149489.
• J.Rissier et al., Nature, 298, 221 (1982)

Trifluoroacetic acid (TFA) is a common counterion from the purification process using High-Performance Liquid Chromatography (HPLC). The presence of TFA can affect the peptide's net weight, appearance, and solubility.

Impact on Net Weight: The TFA salt contributes to the total mass of the product. In most cases, the peptide content constitutes >80% of the total weight, with TFA accounting for the remainder.

Solubility: TFA salts generally enhance the solubility of peptides in aqueous solutions.

In Biological Assays: For most standard in vitro assays, the residual TFA levels do not cause interference. However, for highly sensitive cellular or biochemical studies, please be aware of its presence.